What does SANUWAVE Health do?
SANUWAVE Health, Inc. is a small-cap medical-device company focused on directed-energy wound care. Its commercial center is UltraMIST, a portable system that delivers low-frequency, non-thermal ultrasound through a saline mist without contacting the wound. The company says the therapy is intended to stimulate tissue repair, reduce inflammation and pain, disrupt bacteria and biofilm, and support blood-vessel growth. UltraMIST is used for acute and chronic wounds including diabetic foot ulcers, venous leg ulcers, pressure injuries, graft sites, and surgical wounds.
The company’s 2025 Form 10-K identifies UltraMIST as its only currently marketed commercial product and states that the portfolio is supported by more than 60 patents. The therapy has FDA clearance and Category I CMS reimbursement under code 97610, so adoption depends not only on clinical acceptance but also on whether providers can integrate treatments into workflow and billing.
How does SANUWAVE Health make money?
Why is this a razor-and-blade model?
Customers buy an UltraMIST generator and treatment wand, then use a sterile, single-use applicator for each treatment. The equipment sale creates the installed base; recurring applicator purchases monetize utilization. Systems are sold through direct representatives, independent distributors, and resellers into hospitals, physician offices, wound centers, skilled nursing facilities, nursing homes, and mobile wound-care practices. Typical treatment time is about six minutes, although treatment can range from three to 20 minutes.
Which revenue stream is strategically most important?
Consumables are the higher-quality stream because they recur when systems are actively used. At December 31, 2025, SANUWAVE reported 1,292 active systems, defined generally as systems whose owners had ordered applicators within the previous six months or their expected ordering cycle. FY2025 consumable unit volume rose 24%, while system unit sales increased 67%. The company’s strategic trade-off is clear: reseller distribution can accelerate placements, but reseller mix can lower system pricing and gross margin.
| Revenue engine | FY2025 evidence | Economic interpretation |
|---|---|---|
| Applicators | About 58% of total revenue; unit volume up 24%; average price up 3% | Recurring utilization revenue and the principal source of model quality. |
| Systems | Unit sales up 67%; average price down 3% | Placements expand the future consumable base, but mix and used-device competition matter. |
| Reseller channel | 34% of FY2025 system sales versus none in FY2024 | Faster distribution can trade near-term price for installed-base growth. |
| Warranty and service | Contract liabilities of $1.2M at March 31, 2026 | Deferred revenue is smaller, but accounting discipline is important after the warranty restatement. |
What do the latest reported results show?
The newest signal is not a complete earnings package. In its preliminary Q2 2026 release, management said capital-equipment sales faced pressure from financially stressed wound-care customers and from a secondary market in used UltraMIST systems. At the same time, applicator unit sales and applicator revenue reached company records. That divergence matters: softer system sales can slow new installed-base growth, while record consumables suggest stronger utilization of systems already in the field.
What changed in Q1 2026?
| Metric | Q1 2026 | Q1 2025 restated | Interpretation |
|---|---|---|---|
| Revenue | $9.619M | $9.333M | Consumable units rose 22%, but systems sold fell 1%. |
| Gross profit | $7.431M | $7.375M | Gross profit increased only 1% as reseller mix pressured pricing. |
| Operating result | $(1.124)M | $0.601M | Selling, marketing, and R&D investment outpaced revenue growth. |
| Net result | $(1.439)M | $(6.118)M | The comparison improved because warrant fair-value expense did not recur. |
| Adjusted EBITDA | $1.089M | $2.252M | Underlying earnings softened despite positive adjusted EBITDA. |
The Q1 2026 Form 10-Q shows the pricing tension directly: average selling price fell 6% for disposables and 11% for systems, while UltraMIST represented 100% of quarterly revenue. The business therefore entered Q2 with good consumable volume but weaker price and capital-equipment conditions.
Consumable growth and margin discipline define the current model
Why does a high gross margin not guarantee operating profit?
SANUWAVE’s product gross margin is attractive for a medical-device company, but the operating base is still heavy relative to quarterly revenue. In Q1 2026, general and administrative expense was $5.3M, selling and marketing was $2.4M, R&D was $0.7M, and depreciation and amortization was $0.2M. Combined operating expenses of $8.6M exceeded gross profit of $7.4M. Selling and marketing rose 57% year over year and R&D rose 217%, showing that management was investing ahead of the quarter’s 3% revenue growth.
What does the quarterly revenue pattern say?
Which turning points shaped SANUWAVE Health?
-
2004The Nevada corporation was formed, beginning a long development path in regenerative medicine and directed energy.
-
2020SANUWAVE acquired the MIST Therapy and UltraMIST assets from Celularity for aggregate consideration disclosed at $24M, making non-contact ultrasound the core commercial platform.
-
2022–2023Morgan Frank became chairman in August 2022 and CEO in May 2023, bringing a capital-markets and corporate-restructuring orientation.
-
2024A 1-for-375 reverse split, a $10.3M private placement, and conversion of outstanding notes and warrants simplified the equity and debt structure.
-
2025Shares began trading on Nasdaq on March 7; the company sold the PACE product line and concentrated the commercial story on UltraMIST.
-
2025A JPMorgan-led facility refinanced legacy debt with a $23M term loan and a $5M revolver, extending maturities and lowering interest burden.
-
2026The 2025 Form 10-K restated prior periods for sales taxes and warranty accounting, while preliminary Q2 results exposed used-system and customer-budget pressure.
Why did the Nasdaq uplisting matter?
The company’s Nasdaq listing announcement marked a transition from an OTC-traded, heavily financed development company toward a more conventional public medical-device profile. It improved market access but also increased governance, audit, disclosure, and investor-relations costs. Those costs are visible in the expanded G&A base.
What gives SANUWAVE a competitive advantage?
How durable is the moat?
The moat is narrower than that of a diversified medtech leader. SANUWAVE has one commercial platform, limited scale, and competitors with much larger sales forces and product portfolios. Its advantage is therefore specific: a differentiated treatment modality, recurring consumables, clinical usability, and reimbursement. The company’s product materials emphasize the patient-friendly, non-contact nature of UltraMIST, while the filing emphasizes short treatment time and portability.
| Competitive field | Named participants | Pressure on SANUWAVE |
|---|---|---|
| Broad wound-care portfolios | Solventum, Smith & Nephew, Mölnlycke, Essity, Coloplast, Convatec | Scale, contracting power, established distribution, and portfolio bundling. |
| Biologic and tissue products | Organogenesis, MiMedx, Integra, Vericel, Kerecis | Alternative treatment pathways and reimbursement-driven physician preferences. |
| Energy-based therapies | Arobella, NanoVibronix, SoftWave | Closer modality competition on ultrasound and acoustic-wave approaches. |
| Used UltraMIST systems | Secondary-market sellers | Direct cannibalization of new system sales, plus training and product-liability complexity. |
How financially strong is SANUWAVE Health?
What did FY2025 improve?
| Metric | FY2025 | FY2024 restated | Meaning |
|---|---|---|---|
| Revenue | $44.051M | $32.634M | 35% growth from higher system and applicator volumes. |
| Gross margin | 77% | 75% | Pricing and lower system costs improved unit economics. |
| Operating income | $4.945M | $3.848M | Core operations were profitable in both restated years. |
| Net income | $11.813M | $(33.083)M | FY2025 benefited from non-operating fair-value changes and a $5M patent payment. |
| Operating cash flow | $3.876M | $2.455M | Positive cash generation supports debt service, but scale remains modest. |
| Adjusted EBITDA | $13.632M | $7.162M | Management’s non-GAAP measure improved, though exclusions were material. |
How should debt and liquidity be read?
At March 31, 2026, current assets were $24.0M and current liabilities were $18.3M, producing positive working capital of roughly $5.7M. Total assets were $37.1M, total liabilities were $35.3M, and equity was only $1.8M. The capital structure is therefore improved but still thin. The September 2025 JPMorgan credit agreement provided a $23M secured term loan maturing in 2029 and a $5M revolver maturing in 2027. The company repaid $1.4M of term-loan principal in Q1 2026, making cash conversion and covenant compliance important operating KPIs.
Who owns SANUWAVE stock, and how is it governed?
SANUWAVE has one common share class with one vote per share. The ownership profile is concentrated for a company of its size: CEO and chairman Morgan Frank beneficially owned 11.8% as of the April 20, 2026 record date, while all current directors and executive officers as a group owned 14.4%. Opaleye held 11.0%, Manchester-related entities and James Besser held 10.8%, AWM held 7.0%, and BlackRock held 5.5%.
| Governance feature | 2026 proxy disclosure | Investor implication |
|---|---|---|
| Board composition | Five directors; four classified as independent | Independent majority provides formal oversight. |
| Leadership | Morgan Frank serves as CEO and chairman | Concentrates strategic authority and accountability. |
| Lead director | Ian Miller | Provides an independent counterweight to combined CEO-chair roles. |
| CEO pay structure | $3,704 salary and $410,383 option awards in FY2025 | Compensation is heavily equity-linked rather than cash-salary driven. |
The 2026 proxy statement also reports that the five-member board held four meetings in 2025 and each incumbent director attended at least 75% of applicable board and committee meetings. For a microcap company, concentrated knowledgeable ownership can align incentives, but overlapping fund, director, and executive relationships deserve careful related-party and voting-power review.
Which KPIs matter most for SANUWAVE?
How should researchers connect the KPIs?
A useful operating chain is: system placements expand the installed base; active systems create treatment capacity; treatment frequency drives applicator volume; applicator price and mix determine recurring revenue; gross margin funds selling, support, R&D, and administration; operating cash flow must then cover debt amortization and reinvestment. A break anywhere in that chain changes valuation. For example, record applicator sales can support near-term cash flow even when capital sales slow, but weaker placements may eventually limit future consumable growth.
What opportunities and risks could change the story?
Where can growth come from?
The largest opportunity is deeper penetration of U.S. wound-care settings. The company estimates the U.S. wound-care market exceeds $67B annually, while its active system count remains small relative to the number of hospitals, clinics, skilled nursing facilities, and mobile providers. Growth can come from more placements, higher treatments per system, reseller reach, certified pre-owned trade-ins, and broader adoption of evidence-based, outpatient wound care. International expansion is an option, but current revenue and assets are overwhelmingly U.S.-based.
Which filing risks are most material?
| Risk | Financial channel | Metric to monitor |
|---|---|---|
| Used-system secondary market | Lower new-system units, lower price, and possible liability or training costs | System units, average selling price, certified pre-owned conversions |
| Customer financial distress | Delayed capital purchases, receivable losses, or practice closures | Accounts receivable, credit-loss allowance, system backlog |
| Reimbursement change | Provider economics and treatment demand | CMS coverage, code 97610 utilization, customer purchasing behavior |
| Single-product concentration | A regulatory, quality, supply, or clinical issue affects nearly all revenue | UltraMIST share of revenue, complaints, recalls, supply disruptions |
| Supplier dependence | Generator, wand, or applicator shortages can interrupt sales | Inventory, lead times, gross margin, alternative sourcing |
| Debt and covenants | Cash principal payments compete with growth investment | Operating cash flow, revolver availability, covenant compliance |
| Internal controls | Restatements raise audit cost and reduce confidence in reported trends | Remediation disclosures and future control deficiencies |
Why does SANUWAVE matter for valuation?
Which drivers belong in a DCF?
A SANUWAVE valuation should separate recurring applicator economics from capital-equipment sales. Revenue growth depends on active systems, new placements, treatment frequency, applicator pricing, reseller mix, and the used-device market. Gross margin should be modeled separately for systems and consumables where possible because channel mix can lower pricing even when volume rises. Operating leverage depends on whether selling and administrative spending grows slower than gross profit.
| Valuation driver | Base evidence | DCF consequence |
|---|---|---|
| Installed-base growth | 1,292 active systems at FY2025 year-end | Raises the addressable pool for recurring applicator revenue. |
| Consumable utilization | 58% of FY2025 revenue; record preliminary Q2 2026 activity | Supports higher revenue quality and potentially steadier cash flow. |
| Gross margin | 77% in FY2025 and Q1 2026 | Small pricing or mix changes have a large effect on operating profit. |
| Operating expense discipline | $8.6M in Q1 2026 versus $7.4M gross profit | Determines whether revenue growth converts into sustainable EBIT. |
| Debt service | $20.8M combined term and revolver borrowings at March 31, 2026 | Reduces equity value and increases sensitivity to cash-flow misses. |
| Terminal risk | Single product, reimbursement exposure, and microcap scale | Supports a higher discount rate and conservative terminal assumptions. |
Net income is a poor starting point for normalized free cash flow because FY2025 included an $8.1M favorable derivative-liability change and a $5M patent payment. A cleaner approach begins with operating income, adjusts for taxes and non-cash expenses, subtracts working-capital needs and capitalized software or equipment spending, and then tests whether cash flow covers scheduled principal. The company’s official investor presentations can supplement filings, but restated SEC figures should remain the valuation baseline.
What is the key takeaway from SANUWAVE Health analysis?
SANUWAVE is a focused wound-care company whose economics are becoming easier to understand. UltraMIST placements create a base of systems; patient treatments consume applicators; applicator reorders produce recurring revenue. FY2025 demonstrated that the model can generate high gross margin, operating income, and positive operating cash flow. The debt refinancing, Nasdaq listing, and disposal of the PACE line also simplified the corporate story.
The latest evidence is mixed rather than uniformly positive. Q1 2026 consumable volume grew, but price fell and operating expenses expanded faster than revenue. Preliminary Q2 2026 revenue declined year over year as capital sales weakened, yet applicator sales reached records. This makes utilization the strongest near-term signal and system placements the most important longer-term signal.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.